Home > Press > Nanomedicine journal receives rapid acceptance by ISI Science Citation Index
Abstract:
Future Medicine Ltd announced today that its journal Nanomedicine (ISSN:
1743-5889) has been selected for coverage in ISI® services after the publication
of only five issues.
Nanomedicine journal receives rapid acceptance by ISI Science Citation Index
London, UK | Posted on February 21st, 2007"We at Nanomedicine are delighted that the journal has been accepted for
coverage by ISI after only one year. This speaks not only to the importance of
the field, but also to the high quality of the articles and features published to date
in Nanomedicine. We also recognize that the outstanding scientists on our
editorial advisory board played a large role in the rapid development of
Nanomedicine, and we look forward to continuing fruitful interactions with the
board and with all the authors who choose to publish their excellent work in
Nanomedicine.", says Professor Charles R Martin, Director of the Center for
Research at the Bio/Nano Interface and Colonel Allen R and Margaret G Crow
Professor of Chemistry, University of Florida (FL, USA), and Senior Editor of the
journal.
Kostas Kostarelos, Centre for Drug Delivery Research, University of London (UK)
and also Senior Editor of the journal commented; "Recognition by the Institute of
Scientific Information is considered by all of us in the journal as an indication that
nanomedicine is entering the mainstream of scientific advance and that the
journal Nanomedicine is at the forefront of this field. We are determined to grow
stronger as a journal and contribute to medical practice as a whole."
Topics covered in the first year of publication by Nanomedicine include basic
research and theoretical applications of nanomedical technology, potential
medical applications and therapeutic applications of nanotechnology advances,
nanomedical tools in gene therapy, drug delivery and commercialization, funding,
economics and ethics of nanomedical technology.
Morag Robertson, Editor at Future Medicine said; "We are delighted that
Nanomedicine has been accepted by Thomson ISI at this early stage of the
journal's development. The field of nanotechnology and its medical applications
has become one of the hottest areas in science today and the launch of
Nanomedicine has been greeted with huge interest. We would like to thank the
journal's Senior Editors, Professor Charles Martin and Dr Kostas Kostarelos, for
their encouragement as well as our outstanding Editorial Board for their input and
guidance thus far. We anticipate further success with Nanomedicine as we move
forward."
The Senior Editors and Future Medicine Ltd aim to make Nanomedicine the main
forum in which the challenges and advances in nanotechnology research related
to medicine are addressed. In upcoming years, the field promises much -
Nanomedicine will be there to highlight the main advances and therapeutic
possibilities for clinicians and researchers alike and will provide an avenue for
debate of controversial issues.
####
About FUTURE SCIENCE GROUP
Future Science Group Ltd, based in London has developed an innovative publishing portfolio to reflect post-genomic medicine. The sequencing of the human genome was a colossal milestone in the evolution of healthcare, with repercussions for all those involved in the healthcare chain. Through its imprints, Future Medicine, Future Drugs and Future Biology, the Future Science Group provides healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in the light of these advances. Our flagship title Pharmacogenomics has evolved to become a leading source of commentary and analysis from international opinion leaders. Momentum toward an individualized approach to medicine is increasing as the value of linking diagnostic and therapeutic approaches becomes ever clearer. For more information please access http://www.future-drugs.com , http://www.futuremedicine.com and http://www.future-biology.com
For more information, please click here
Contacts:
Simon Boisseau
Marketing Manager
Future Science Group
T: +44 (0) 20 8349 2033
F: +44 (0) 20 8343 2313
Copyright © FUTURE SCIENCE GROUP
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
| Related News Press |
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||